Skip to main content
Mikhail Roshal, MD, Pathology, New York, NY, Memorial Sloan Kettering Cancer Center

MikhailRoshalMD

Pathology New York, NY

Hematopathology, Anatomic Pathology, Clinical Pathology

Assistant Professor, Pathology & Laboratory Medicine, Weill Cornell Medical College

Dr. Roshal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Roshal's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematopathology, 2009 - 2010
  • University of Washington
    University of WashingtonResidency, Pathology-Anatomic and Clinical, 2005 - 2008
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 2005

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2010 - 2025
  • NJ State Medical License
    NJ State Medical License 2021 - 2025
  • WA State Medical License
    WA State Medical License 2007 - 2010
  • American Board of Pathology Pathology - Clinical
  • American Board of Pathology Hematopathology

Publications & Presentations

PubMed

Journal Articles

  • Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
    Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature

Abstracts/Posters

  • Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
    Mikhail Roshal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
    Mikhail Roshal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
    Mikhail Roshal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations